Soy isoflavones improve cardiovascular disease risk markers in women during the early menopause

T. Sathyapalan, M. Aye, A. S. Rigby, N. J. Thatcher, Soha Dargham, E. S. Kilpatrick, Stephen Atkin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Hormone replacement therapy may be beneficial for cardiovascular disease risk (CVR) in post-menopausal women. Soy isoflavones may act as selective estrogen receptor modulators. The aim of this study was to evaluate whether soy isoflavones had an effect on CVR markers. Methods: The expected 10-year risk of cardiovascular disease and mortality were calculated as a secondary endpoint from a double blind randomised parallel study involving 200 women (mean age 55 years, Caucasian, Hull, UK, 2012) in the early menopause who were randomised to 15 g soy protein with 66 mg isoflavone (SPI) or 15 g soy protein alone (depleted of all isoflavones; SP) given as a snack bar between meals daily for 6 months. Age, diabetes, smoking, blood pressure and lipid profiles were used to calculate CVR using the Framingham CVR engine. Results: SPI treatment resulted in a significant reduction in the metabolic parameters and systolic blood pressure compared to SP (p < 0.01). There were no changes in fasting lipid profile and diastolic blood pressure with either treatment. At 6 months, changes in these parameters with SPI treatment were reflected in a calculated 27% (p < 0.01) reduction in 10 year coronary heart disease risk, a 37% (p < 0.01) reduction in myocardial infarction risk, a 24% (p < 0.04) reduction in cardiovascular disease and 42% (p < 0.02) reduction in cardiovascular disease death risk. Conclusions: Supplementation with soy protein with isoflavones for 6 months significantly improved CVR markers and calculated CVR at 6 months during early menopause compared to soy protein without isoflavones. ISRCTN registry: ISRCTN34051237.

Original languageEnglish
JournalNutrition, Metabolism and Cardiovascular Diseases
DOIs
Publication statusAccepted/In press - 1 Jan 2018

Fingerprint

Isoflavones
Menopause
Cardiovascular Diseases
Soybean Proteins
Blood Pressure
Lipids
Selective Estrogen Receptor Modulators
Snacks
Hormone Replacement Therapy
Coronary Disease
Meals
Registries
Fasting
Therapeutics
Smoking
Myocardial Infarction

Keywords

  • Cardiovascular death
  • Cardiovascular disease
  • Cardiovascular risk
  • Isoflavones
  • Postmenopausal
  • Soy
  • Stroke

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine

Cite this

Soy isoflavones improve cardiovascular disease risk markers in women during the early menopause. / Sathyapalan, T.; Aye, M.; Rigby, A. S.; Thatcher, N. J.; Dargham, Soha; Kilpatrick, E. S.; Atkin, Stephen.

In: Nutrition, Metabolism and Cardiovascular Diseases, 01.01.2018.

Research output: Contribution to journalArticle

@article{05e95f06e9a44e9ca03bde05ee670fea,
title = "Soy isoflavones improve cardiovascular disease risk markers in women during the early menopause",
abstract = "Background: Hormone replacement therapy may be beneficial for cardiovascular disease risk (CVR) in post-menopausal women. Soy isoflavones may act as selective estrogen receptor modulators. The aim of this study was to evaluate whether soy isoflavones had an effect on CVR markers. Methods: The expected 10-year risk of cardiovascular disease and mortality were calculated as a secondary endpoint from a double blind randomised parallel study involving 200 women (mean age 55 years, Caucasian, Hull, UK, 2012) in the early menopause who were randomised to 15 g soy protein with 66 mg isoflavone (SPI) or 15 g soy protein alone (depleted of all isoflavones; SP) given as a snack bar between meals daily for 6 months. Age, diabetes, smoking, blood pressure and lipid profiles were used to calculate CVR using the Framingham CVR engine. Results: SPI treatment resulted in a significant reduction in the metabolic parameters and systolic blood pressure compared to SP (p < 0.01). There were no changes in fasting lipid profile and diastolic blood pressure with either treatment. At 6 months, changes in these parameters with SPI treatment were reflected in a calculated 27{\%} (p < 0.01) reduction in 10 year coronary heart disease risk, a 37{\%} (p < 0.01) reduction in myocardial infarction risk, a 24{\%} (p < 0.04) reduction in cardiovascular disease and 42{\%} (p < 0.02) reduction in cardiovascular disease death risk. Conclusions: Supplementation with soy protein with isoflavones for 6 months significantly improved CVR markers and calculated CVR at 6 months during early menopause compared to soy protein without isoflavones. ISRCTN registry: ISRCTN34051237.",
keywords = "Cardiovascular death, Cardiovascular disease, Cardiovascular risk, Isoflavones, Postmenopausal, Soy, Stroke",
author = "T. Sathyapalan and M. Aye and Rigby, {A. S.} and Thatcher, {N. J.} and Soha Dargham and Kilpatrick, {E. S.} and Stephen Atkin",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.numecd.2018.03.007",
language = "English",
journal = "Nutrition, Metabolism and Cardiovascular Diseases",
issn = "0939-4753",
publisher = "Elsevier",

}

TY - JOUR

T1 - Soy isoflavones improve cardiovascular disease risk markers in women during the early menopause

AU - Sathyapalan, T.

AU - Aye, M.

AU - Rigby, A. S.

AU - Thatcher, N. J.

AU - Dargham, Soha

AU - Kilpatrick, E. S.

AU - Atkin, Stephen

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Hormone replacement therapy may be beneficial for cardiovascular disease risk (CVR) in post-menopausal women. Soy isoflavones may act as selective estrogen receptor modulators. The aim of this study was to evaluate whether soy isoflavones had an effect on CVR markers. Methods: The expected 10-year risk of cardiovascular disease and mortality were calculated as a secondary endpoint from a double blind randomised parallel study involving 200 women (mean age 55 years, Caucasian, Hull, UK, 2012) in the early menopause who were randomised to 15 g soy protein with 66 mg isoflavone (SPI) or 15 g soy protein alone (depleted of all isoflavones; SP) given as a snack bar between meals daily for 6 months. Age, diabetes, smoking, blood pressure and lipid profiles were used to calculate CVR using the Framingham CVR engine. Results: SPI treatment resulted in a significant reduction in the metabolic parameters and systolic blood pressure compared to SP (p < 0.01). There were no changes in fasting lipid profile and diastolic blood pressure with either treatment. At 6 months, changes in these parameters with SPI treatment were reflected in a calculated 27% (p < 0.01) reduction in 10 year coronary heart disease risk, a 37% (p < 0.01) reduction in myocardial infarction risk, a 24% (p < 0.04) reduction in cardiovascular disease and 42% (p < 0.02) reduction in cardiovascular disease death risk. Conclusions: Supplementation with soy protein with isoflavones for 6 months significantly improved CVR markers and calculated CVR at 6 months during early menopause compared to soy protein without isoflavones. ISRCTN registry: ISRCTN34051237.

AB - Background: Hormone replacement therapy may be beneficial for cardiovascular disease risk (CVR) in post-menopausal women. Soy isoflavones may act as selective estrogen receptor modulators. The aim of this study was to evaluate whether soy isoflavones had an effect on CVR markers. Methods: The expected 10-year risk of cardiovascular disease and mortality were calculated as a secondary endpoint from a double blind randomised parallel study involving 200 women (mean age 55 years, Caucasian, Hull, UK, 2012) in the early menopause who were randomised to 15 g soy protein with 66 mg isoflavone (SPI) or 15 g soy protein alone (depleted of all isoflavones; SP) given as a snack bar between meals daily for 6 months. Age, diabetes, smoking, blood pressure and lipid profiles were used to calculate CVR using the Framingham CVR engine. Results: SPI treatment resulted in a significant reduction in the metabolic parameters and systolic blood pressure compared to SP (p < 0.01). There were no changes in fasting lipid profile and diastolic blood pressure with either treatment. At 6 months, changes in these parameters with SPI treatment were reflected in a calculated 27% (p < 0.01) reduction in 10 year coronary heart disease risk, a 37% (p < 0.01) reduction in myocardial infarction risk, a 24% (p < 0.04) reduction in cardiovascular disease and 42% (p < 0.02) reduction in cardiovascular disease death risk. Conclusions: Supplementation with soy protein with isoflavones for 6 months significantly improved CVR markers and calculated CVR at 6 months during early menopause compared to soy protein without isoflavones. ISRCTN registry: ISRCTN34051237.

KW - Cardiovascular death

KW - Cardiovascular disease

KW - Cardiovascular risk

KW - Isoflavones

KW - Postmenopausal

KW - Soy

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85046703845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046703845&partnerID=8YFLogxK

U2 - 10.1016/j.numecd.2018.03.007

DO - 10.1016/j.numecd.2018.03.007

M3 - Article

JO - Nutrition, Metabolism and Cardiovascular Diseases

JF - Nutrition, Metabolism and Cardiovascular Diseases

SN - 0939-4753

ER -